AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37084261
Drug: Intrathecal oxytocin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal oxytocin, 100 µg
Trial: 37084342
Drug: Elafibranor 120
RxNorm normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elafibranor 120 mg daily for 12 weeks
Trial: 37084342
Drug: Elafibranor 80
RxNorm normalized name: elafibranor 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elafibranor 80 mg daily for 12 weeks
Trial: 37084383
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose total body irradiation (200 cGy)
Trial: 37084401
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (active vitamin D and phosphate)
Trial: 37084590
Drug: Low-fat, vegan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, vegan diet including cooked soybeans (1/2 cup [86 g]/day) for 12 weeks
Trial: 37084748
Drug: Proton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton therapy (54 Gy with a 0.5 cm clinical target volume margin) combined with limited surgery
Trial: 37084803
Drug: AGuIX®-based radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGuIX®-based radiation treatments
Trial: 37085287
Drug: Ropivacaine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 150 mg followed by boluses of 40 mg every 6 hours and infusion of 2 mg/hour
Trial: 37085287
Drug: Weight-based ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based ropivacaine dosing
Trial: 37085880
Drug: Anticholinergic bladder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic bladder therapy (tolterodine 2 mg ER)
Trial: 37085880
Drug: Beta-3 adrenergic
RxNorm normalized name: Product containing beta-3 adrenergic receptor agonist (product)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-3 adrenergic agonist bladder therapy (mirabegron 25 mg ER)
Trial: 37085899
Drug: Meals delivered
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meals delivered daily to participants' homes by a volunteer or paid driver who socializes with the client
Trial: 37086054
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for insomnia (CBTI)
Trial: 37086083
Drug: 24-hour ambulatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour ambulatory blood pressure monitoring (ABPM) in CIS patients without antihypertensives
Trial: 37086340
Drug: DMT fumarate
RxNorm normalized name: fumarate
DrugBank: Dimethyltryptamine (DB01488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMT fumarate (SPL026) administered via a two-phase intravenous (IV) infusion, escalating doses of 9-21.5 mg (DMT freebase) over a 10-min infusion.
Trial: 37086595
Drug: LEN+PEMBRO (Lenvatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEN+PEMBRO (Lenvatinib 20 mg/day + Pembrolizumab 200 mg Q3W)
Trial: 37086595
Drug: TPC (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPC (Treatment of Physician's Choice, doxorubicin 60 mg/m2)
Trial: 37086745
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (5.4 mg/kg intravenously once every 3 weeks)
Trial: 37086745
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of physician's choice (capecitabine 1250 mg/m2)
Trial: 37086916
Drug: Minimal intervention
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal intervention including a Fitbit linked with clinic's patient portal and EHR with weekly feedback
Trial: 37087399
Drug: Axitinib modifications
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Axitinib modifications (dose reduction or treatment interruption)
Trial: 37087459
Drug: Weekly Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly Abatacept + Methotrexate
Trial: 37087459
Drug: Abatacept Monotherapy
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept Monotherapy
Trial: 37087950
Drug: ide-cel treatment
RxNorm normalized name: IDE-CEL
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ide-cel treatment
Trial: 37088275
Drug: Continuous glucose
RxNorm normalized name: sub-q infusion pump w/continuous glucose monitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous glucose monitoring (Dexcom G6 Pro) for 10 days starting at the 50-g glucose challenge test.
Trial: 37088447
Drug: Surgery (PPV,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery (PPV, subretinal tPA [maximum, 0.5 ml/50 μg], and 20% sulfur hexafluoride)
Trial: 37088447
Drug: Pneumatic displacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumatic displacement (PD) with tPA and VEGF inhibitor
Trial: 37088458
Drug: Pegbelfermin (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegbelfermin (10, 20, or 40 mg)
Trial: 37088458
Drug: Pegbelfermin (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegbelfermin (10, 20, or 40 mg) injected subcutaneously once weekly for 48 weeks
Trial: 37088458
Drug: Placebo injected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected subcutaneously once weekly for 48 weeks
Trial: 37088458
Drug: Pegbelfermin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegbelfermin (20 or 40 mg)
Trial: 37088458
Drug: 40-mg pegbelfermin
RxNorm normalized name: Pegbelfermin
DrugBank: Pegbelfermin (DB15365)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40-mg pegbelfermin
Trial: 37088866
Drug: Restorex penile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restorex penile traction therapy (RxPTT)
Trial: 37088866
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Tx)
Trial: 37088866
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to no treatment after initial treatment (Group 3)
Trial: 37088964
Drug: 4CMenB and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB and MenACWY vaccines
Trial: 37089721
Drug: Systemic and
RxNorm normalized name: Estradiol and Levonorgestrel Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic and topical medications
Trial: 37090089
Drug: Lipid-lowering therapies
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapies (LLTs)
Trial: 37093072
Drug: IMMUNOREACT 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMMUNOREACT 1 cohort (therapy naive)
Trial: 37093072
Drug: IMMUNOREACT 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMMUNOREACT 2 cohort (patients who had neoadjuvant therapy)
Trial: 37093160
Drug: Oral Cannabidiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Cannabidiol
Trial: 37093466
Drug: SYHA1402 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1402 25 mg
Trial: 37093466
Drug: SYHA1402 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1402 50 mg
Trial: 37093466
Drug: SYHA1402 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1402 100 mg
Trial: 37093466
Drug: SYHA1402 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1402 200 mg
Trial: 37093466
Drug: SYHA1402 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1402 400 mg
Trial: 37093466
Drug: SYHA1402 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1402 800 mg
Trial: 37093466
Drug: SYHA1402 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1402 (all doses)
Trial: 37093466
Drug: SYHA1402 (25-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYHA1402 (25-100 mg)
Trial: 37093572
Drug: Transvaginal pudendal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvaginal pudendal nerve block (9 mL 0.25% bupivacaine and 1 mL 40 mg/mL triamcinolone)
Trial: 37093572
Drug: Sham injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham injection (10 mL normal saline)
Trial: 37093833
Drug: Hormone monotherapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone monotherapy
Trial: 37093892
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies (nAbs) from plasma samples of SFV-infected individuals
Trial: 37093892
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies (nAbs)
Trial: 37094349
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) and Cash transfer together
Trial: 37094596
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with rituximab
Trial: 37094668
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy after 3-month dual antiplatelet therapy
Trial: 37094668
Drug: Ticagrelor plus
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor plus aspirin after 3-month dual antiplatelet therapy
Trial: 37094892
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy combined with therapeutic exercise for 10 weeks (two visits per week)
Trial: 37094943
Drug: 0.6% Lugol's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6% Lugol's solution
Trial: 37094943
Drug: 1.2% Lugol's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% Lugol's solution
Trial: 37094968
Drug: Patient blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient blood management program (high-dose iron supplements before and after surgery)
Trial: 37094988
Drug: Intravenous enadenotucirev
RxNorm normalized name: Enadenotucirev
DrugBank: Enadenotucirev (DB14873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous enadenotucirev plus nivolumab
Trial: 37095120
Drug: Single-target CD19
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-target CD19 CAR T-cell therapy
Trial: 37095120
Drug: Dual-target tandem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-target tandem CD19/CD22 CAR T-cell therapy
Trial: 37095120
Drug: Dual-target sequential
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-target sequential CD19/CD22 CAR T-cell therapy
Trial: 37095250
Drug: Tau-targeting antisense
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tau-targeting antisense oligonucleotide (MAPT), dosage and duration not specified
Trial: 37095298
Drug: Bivalirudin use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin use during operation (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h)
Trial: 37095298
Drug: Bivalirudin use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h)
Trial: 37095378
Drug: Adenoviral and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenoviral and inactivated-virus vaccines (heterologous combinations)
Trial: 37095378
Drug: mRNA vaccine
RxNorm normalized name: RSV mRNA vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA vaccine as the second dose
Trial: 37095378
Drug: Inactivated-virus vaccine
RxNorm normalized name: Japanese Encephalitis Virus Vaccine Inactivated
DrugBank: Japanese Encephalitis Virus Vaccine Inactivated (DB19294)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated-virus vaccine (priming)
Trial: 37095378
Drug: Boosting with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosting with inactivated-virus vaccine
Trial: 37095378
Drug: Different vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different vaccine combinations
Trial: 37095561
Drug: Integrated HCV
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated HCV treatment
Trial: 37095561
Drug: Standard HCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard HCV treatment
Trial: 37095571
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted motivational interviewing with cognitive behavior therapy and mindfulness-based relapse prevention, delivered weekly over a period of 12 weeks.
Trial: 37095689
Drug: Third-dose triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-dose triple combination therapy (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg)
Trial: 37095689
Drug: Third-dose dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-dose dual combination therapy (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg)
Trial: 37095689
Drug: Third-dose dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-dose dual combination therapy (LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg)
Trial: 37095689
Drug: Third-dose dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-dose dual combination therapy (AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg)
Trial: 37095689
Drug: Third-dose triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third-dose triple combination therapy (ALC group)
Trial: 37096093
Drug: Transbronchial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transbronchial injection of iron sucrose, median injection 90 mL (range, 70-120 mL)
Trial: 37096186
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day of raw walnut kernels for 6 months
Trial: 37096188
Drug: Gumarontinib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gumarontinib monotherapy
Trial: 37096402
Drug: Total postoperative
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total postoperative opioid dose (TPOD)
Trial: 37096402
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil dose on postoperative day 1 (POD1)
Trial: 37096402
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia with basal infusion
Trial: 37096495
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo, autologous FMT, no intervention, or antibiotics)
Trial: 37097604
Drug: Nadroparin 5.900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin 5.900 IU subcutaneously twice daily in mechanically ventilated patients
Trial: 37097604
Drug: Nadroparin 5.900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin 5.900 IU subcutaneously once daily in patients supplemented with conventional oxygen
Trial: 37097715
Drug: Pembrolizumab administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab administered three-times weekly for 1 year or until progression, starting 30-45 days after TACE.
Trial: 37098004
Drug: Branched chain
RxNorm normalized name: Branched Chain Amino Acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched chain amino acids (BCAA) intake measured in grams (g) per 1000 kilocalories (kcal) of energy intake (range 3.0-34.8 g/1000 kcal)
Trial: 37098131
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg for 4 weeks)
Trial: 37098409
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg prucalopride for 6 days
Trial: 37098506
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment approaches for problem gambling
Trial: 37098529
Drug: Olipudase alfa
RxNorm normalized name: OLIPUDASE ALFA
DrugBank: Olipudase alfa (DB12835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olipudase alfa enzyme replacement therapy
Trial: 37099280
Drug: Cytoreduction plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreduction plus HIPEC with mitomycin C (30 mg/m2 over 60 minutes)
Trial: 37099280
Drug: Cytoreduction plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreduction plus HIPEC with mitomycin C (30 mg/m2 over 60 minutes) in pT4 subgroup
Trial: 37099295
Drug: IM tixagevimab-cilgavimab
RxNorm normalized name: CILGAVIMAB/TIXAGEVIMAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM tixagevimab-cilgavimab (300 mg IV or 600 mg IM)
Trial: 37099295
Drug: IV tixagevimab-cilgavimab
RxNorm normalized name: CILGAVIMAB/TIXAGEVIMAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tixagevimab-cilgavimab (300 mg IV)
Trial: 37099298
Drug: Repeated low-level
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated low-level red light (RLRL) therapy, twice per day, 5 days per week, each session lasting 3 minutes.
Trial: 37099298
Drug: RLRL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLRL therapy (for those without treatment interruption due to COVID-19).
Trial: 37099341
Drug: BCG-Denmark vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG-Denmark vaccine
Trial: 37099363
Drug: Digital messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital messaging therapy
Trial: 37099376
Drug: TreadWill (unguided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TreadWill (unguided computerized cognitive behavioral therapy)
Trial: 37100160
Drug: Hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy (hypo-RT) followed by hypofractionated boost (hypo-boost) combined with concurrent weekly chemotherapy (docetaxel 25 mg/m2)
Trial: 37100205
Drug: Machine learning-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Machine learning-based immune phenotyping (ML-derived immune phenotypes)
Trial: 37100205
Drug: Concurrent KEAP1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent KEAP1 and STK11 mutations in lung adenocarcinoma (LUAD)
Trial: 37100349
Drug: 250-mg 17-hydroxyprogesterone
RxNorm normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250-mg 17-hydroxyprogesterone caproate
Trial: 37100349
Drug: 500-mg 17-hydroxyprogesterone
RxNorm normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-mg 17-hydroxyprogesterone caproate
Trial: 37100349
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of 17-hydroxyprogesterone caproate
Trial: 37100687
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake <150 μg/d
Trial: 37100687
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake >550 μg/d
Trial: 37100687
Drug: Daily iodine
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily iodine intake at zero balance
Trial: 37100687
Drug: Iodine intakes
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intakes <150 μg/d and >550 μg/d
Trial: 37100705
Drug: 2-week placebo
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week placebo modulator study
Trial: 37100705
Drug: 6-month placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month placebo modulator study
Trial: 37100705
Drug: 2-week active-comparator
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week active-comparator modulator study
Trial: 37100705
Drug: 6-month active-comparator
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month active-comparator modulator study
Trial: 37100705
Drug: 2-week placebo
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week placebo inhaled antimicrobial study
Trial: 37100705
Drug: 6-month placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month placebo inhaled antimicrobial study
Trial: 37100891
Drug: Longer daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer daily eating window
Trial: 37101251
Drug: Stimulant use
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant use (primarily meth)
Trial: 37101251
Drug: Stimulant use
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant use